Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

By Kristin Jensen • Dec. 22, 2025

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

By BioPharma Dive staff • Dec. 19, 2025

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity. 

By Jonathan Gardner • Dec. 18, 2025

FDA clears GSK’s twice-yearly asthma drug

Exdensur is now the first asthma biologic to be approved for twice-yearly dosing, and could potentially change standard of care for those with severe disease.

By Delilah Alvarado • Updated Dec. 17, 2025

Sanofi MS drug hits two setbacks

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.

By Jacob Bell • Dec. 15, 2025

Novartis notches another win for drug acquired in MorphoSys deal

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low platelet counts.

By Jonathan Gardner • Dec. 9, 2025

Pfizer dips into China for another try at an obesity pill

A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.

By Kristin Jensen • Dec. 9, 2025

FDA raises CAR-T approval standards; Novartis bets on an AI startup

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol Myers Squibb and BioNTech proved effective in breast cancer patients.

By BioPharma Dive staff • Dec. 9, 2025

J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

By Jonathan Gardner • Dec. 9, 2025

How digital companion apps unlock value across the drug lifecycle

Where companion apps unlock value across the full drug lifecycle, from Pre-Rx to Post-Rx.

Dec. 8, 2025

At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care. 

By Jonathan Gardner • Dec. 7, 2025

After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

By Jacob Bell • Dec. 3, 2025

Specialty pharmacy’s secret weapon: The unsung power of the enrollment form

One form can make or break orphan drug success and patient outcomes.

Dec. 1, 2025

Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3

The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

By BioPharma Dive staff • Nov. 26, 2025

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

By Jonathan Gardner • Nov. 26, 2025

Novartis wins approval to use SMA gene therapy in older patients

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor function.

By Jonathan Gardner • Nov. 25, 2025

How do Big Pharma employees rate their CEOs?

Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.

By Alexandra Pecci • Nov. 25, 2025

Bayer’s experimental blood-thinner notches trial win in stroke prevention

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

By Jonathan Gardner • Nov. 24, 2025

Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.

By Jacob Bell • Nov. 24, 2025

FDA probes effects of Takeda rare disease drug after patient death

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

By Kristin Jensen • Nov. 24, 2025

Biogen strikes deal with Versant-backed biotech to expand immune portfolio

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."

By Delilah Alvarado • Nov. 24, 2025

Eli Lilly becomes first drugmaker to hit $1 trillion in market value

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.

By Ned Pagliarulo , Jonathan Gardner • Nov. 21, 2025

GSK, Anaptysbio sue each other over Jemperli revenue

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

By Jonathan Gardner • Nov. 21, 2025

Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

By Michael Gibney • Nov. 21, 2025

Roche inks deal for rights to Freenome cancer tests outside US

Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round.

By Nick Paul Taylor • Nov. 20, 2025